Aclarion Company Leadership
| ACON Stock | USD 7.12 0.29 3.91% |
Aclarion employs about 5 people. The company is managed by 4 executives with a total tenure of roughly 12 years, averaging almost 3.0 years of service per executive, having 1.25 employees per reported executive. Analysis of Aclarion's management performance can provide insight into the firm performance.
Aclarion Management Team Effectiveness
The company has return on total asset (ROA) of (0.3544) % which means that it has lost $0.3544 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.7253) %, meaning that it created substantial loss on money invested by shareholders. Aclarion's management efficiency ratios could be used to measure how well Aclarion manages its routine affairs as well as how well it operates its assets and liabilities.Aclarion Workforce Comparison
Aclarion is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 210. Aclarion holds roughly 5.0 in number of employees claiming about 2.38% of equities under Health Care industry.
Aclarion Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Aclarion insiders, such as employees or executives, is commonly permitted as long as it does not rely on Aclarion's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Aclarion insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Neal David K over three months ago Disposition of 152128 shares by Neal David K of Aclarion subject to Rule 16b-3 | ||
Deitsch Stephen over three months ago Acquisition by Deitsch Stephen of 63000 shares of Aclarion subject to Rule 16b-3 | ||
Deitsch Stephen over six months ago Acquisition by Deitsch Stephen of 63000 shares of Aclarion subject to Rule 16b-3 | ||
Neal David K over six months ago Disposition of 66934 shares by Neal David K of Aclarion at 1.94 subject to Rule 16b-3 | ||
Neal David K over a year ago Disposition of 3347 shares by Neal David K of Aclarion at 1.34 subject to Rule 16b-3 | ||
Ryan Bond over a year ago Purchase by Ryan Bond of 20000 shares of Aclarion | ||
Thramann Jeffrey John over a year ago Purchase by Thramann Jeffrey John of tradable shares of Aclarion |
Aclarion Notable Stakeholders
An Aclarion stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Aclarion often face trade-offs trying to please all of them. Aclarion's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Aclarion's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Brent Ness | President CEO | Profile | |
| Jeffrey MD | Executive Chairman | Profile | |
| Ryan Bond | Chief Officer | Profile | |
| John Lorbiecki | Chief Officer | Profile |
About Aclarion Management Performance
The success or failure of an entity such as Aclarion often depends on how effective the management is. Aclarion management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Aclarion management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Aclarion management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy in the United States. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California. Aclarion operates under Health Information Services classification in the United States and is traded on NASDAQ Exchange. It employs 3 people.
Aclarion Workforce Analysis
Traditionally, organizations such as Aclarion use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Aclarion within its industry.Aclarion Manpower Efficiency
Return on Aclarion Manpower
| Revenue Per Employee | 9.1K | |
| Revenue Per Executive | 11.4K | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 1.7M |
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Aclarion. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in persons. To learn how to invest in Aclarion Stock, please use our How to Invest in Aclarion guide.You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Aclarion. If investors know Aclarion will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Aclarion listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Aclarion is measured differently than its book value, which is the value of Aclarion that is recorded on the company's balance sheet. Investors also form their own opinion of Aclarion's value that differs from its market value or its book value, called intrinsic value, which is Aclarion's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Aclarion's market value can be influenced by many factors that don't directly affect Aclarion's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Aclarion's value and its price as these two are different measures arrived at by different means. Investors typically determine if Aclarion is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Aclarion's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.